| Field | Specification |
|---|---|
| Mfr No | |
| Alternative Names | Hypoxia-inducible factor 3-alpha; HIF-3-alpha; HIF3-alpha; Basic-helix-loop-helix-PAS protein MOP7; Class E basic helix-loop-helix protein 17; bHLHe17; HIF3-alpha-1; Inhibitory PAS domain protein; IPAS; Member of PAS protein 7; PAS domain-containing protein 7; HIF3A; BHLHE17, MOP7, PASD7 |
| Cellular Localization | |
| Clonality | |
| Concentration | |
| Host | |
| Immunogen | E.coli-derived human HIF3/HIF3A recombinant protein (Position: Q29-Q480). |
| Isotype | |
| Molecular Weight | |
| Product Type | |
| Reactivity | |
| Reconstitution | |
| Target | |
| UniProt # |
Overview
Anti-HIF3/HIF3A Antibody Picoband® is an antibody for HIF3A detection raised in Rabbit (Polyclonal, Rabbit IgG), with reported reactivity: Human,Mouse,Rat. Commonly used in WB, IHC, Flow Cytometry, ELISA workflows.
Key elements and design rationale
- Target: HIF3A (hypoxia inducible factor 3 subunit alpha); UniProt: Q9Y2N7
- Antibody format: Rabbit, Polyclonal, Rabbit IgG
- Molecular weight: 72 kDa, calculated 64133 MW
- Applications: WB, IHC, Flow Cytometry, ELISA
Vendor description (summary): Boster Bio Anti-HIF3/HIF3A Antibody Picoband® catalog # A03805-3.
Biological background
Biological context: Acts as a transcriptional regulator in adaptive response to low oxygen tension. Acts as a regulator of hypoxia-inducible gene expression (PubMed:11573933, PubMed:16126907, PubMed:19694616, PubMed:20416395, PubMed:21069422). Functions as an inhibitor of angiogenesis in hypoxic cells of the cornea. Plays a role in the development of the cardiorespiratory system. May also be involved in apoptosis (By similarity). Isoform 2: Attenuates the ability of transcription factor HIF1A to bind to hypoxia-responsive elements (HRE) located within the enhancer/promoter of hypoxia-inducible target genes and hence inhibits HRE-driven transcriptional activation. Also inhibits hypoxia-inducible ARNT-mediated gene expression. Isoform 3: Attenuates the ability of transcription factor HIF1A to bind to hypoxia-responsive elements (HRE) located within the enhancer/promoter of hypoxia-inducible target genes and hence inhibits HRE-driven transcriptional activation. isoform 4: Attenuates the ability of transcription factor HIF1A and EPAS1/HIF2A to bind to hypoxia-responsive elements (HRE) located within the enhancer/promoter of hypoxia-inducible target genes and hence inhibits HRE-driven transcriptional activation (PubMed:16126907, PubMed:17998805, PubMed:19694616, PubMed:20416395). May act as a tumor suppressor and inhibits malignant cell transformation (PubMed:17998805). Isoform 5: Attenuates the ability of transcription factor HIF1A to bind to hypoxia-responsive elements (HRE) located within the enhancer/promoter of hypoxia-inducible target genes and hence inhibits HRE-driven transcriptional activation.
Expression and localization notes: cellular localization: Nucleus, nucleoplasm . Cytoplasm . Localized in cytoplasmic mRNP granules containing untranslated mRNAs. These granules are not identical with P bodies or stress granules. ., tissue context: Expressed in vascular cells (at protein level). Expressed in kidney. Expressed in lung epithelial cells. Expressed in endothelial cells (venous and arterial cells from umbilical cord and aortic endothelial cells) and in vascular smooth muscle cells (aorta). Strongly expressed in the heart, placenta, and skeletal muscle, whereas a weak expression profile was found in the lung, liver, and kidney. Expressed weakly in cell renal cell carcinoma (CC-RCC) compared to normal renal cells. Expression is down-regulated in numerous kidney tumor cells compared to non tumor kidney tissues. Isoform 2 is expressed in heart, placenta, lung, liver, skeletal muscle and pancreas and in numerous cancer cell lines. Isoform 3 and isoform 4 are weakly expressed in heart, placenta, lung, liver, skeletal muscle and pancreas. Isoform 4 is expressed in fetal tissues, such as heart, brain, thymus, lung, liver, skeletal kidney and spleen. Isoform 3 is weakly expressed in fetal tissues, such as liver and kidney..
Common research applications
- Western blotting (WB): Compare HIF3A levels across samples and conditions using appropriate loading and biological controls.
- Immunohistochemistry (IHC): Evaluate spatial distribution of HIF3A in tissue sections, considering fixation and antigen retrieval effects.
- Flow cytometry: Quantify HIF3A-positive populations in single-cell suspensions with appropriate gating and controls.
- ELISA: Use antibody-based detection formats to assess antigen presence or binding in plate-based assays.
Notes for experimental interpretation
- Account for isoforms, post-translational modifications, and sample-specific processing that can shift apparent molecular weight or epitope accessibility.
- Use positive/negative biological controls where possible (e.g., known-expressing cells/tissues, knockdown/knockout models) and include appropriate secondary-only/isotype controls for imaging workflows.
Additional product notes (from provided fields)
- Specificity: No cross reactivity with other proteins.
- Background: Hypoxia-inducible factor 3 alpha, also called MOP7, is a protein that in humans is encoded by the HIF3A gene. HIF3A is mapped to 19q13.32. This gene involved in adaptive response to hypoxia. HIF3A suppresses hypoxia-inducible expression of HIF1A and EPAS1. It binds to core DNA sequence 5'-TACGTG-3' within the hypoxia response element (HRE) of target gene promoters. The complex HIF3A-ARNT activates the transcription of reporter genes driven by HRE. This gene functions as an inhibitor of angiogenesis in the cornea.
- Cross reactivity: No cross-reactivity with other proteins.
- Cellular localization: Nucleus, nucleoplasm . Cytoplasm . Localized in cytoplasmic mRNP granules containing untranslated mRNAs. These granules are not identical with P bodies or stress granules. .
- Tissue details: Expressed in vascular cells (at protein level). Expressed in kidney. Expressed in lung epithelial cells. Expressed in endothelial cells (venous and arterial cells from umbilical cord and aortic endothelial cells) and in vascular smooth muscle cells (aorta). Strongly expressed in the heart, placenta, and skeletal muscle, whereas a weak expression profile was found in the lung, liver, and kidney. Expressed weakly in cell renal cell carcinoma (CC-RCC) compared to normal renal cells. Expression is down-regulated in numerous kidney tumor cells compared to non tumor kidney tissues. Isoform 2 is expressed in heart, placenta, lung, liver, skeletal muscle and pancreas and in numerous cancer cell lines. Isoform 3 and isoform 4 are weakly expressed in heart, placenta, lung, liver, skeletal muscle and pancreas. Isoform 4 is expressed in fetal tissues, such as heart, brain, thymus, lung, liver, skeletal kidney and spleen. Isoform 3 is weakly expressed in fetal tissues, such as liver and kidney.
- Research category: DNA/RNA,Epigenetics and Nuclear Signaling,Nucleus,RNA Processing,Subcellular Markers,Tags & Cell Markers
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
